XML 37 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Assets:      
Fair value of assets   $ 351,802 $ 427,084
Liabilities:      
Contingent consideration payable   22,036 19,700
Deferred compensation plan liability   4,003 2,732
Fair value of liabilities   26,039 22,432
Milestone payment, stock issued as consideration   9,000  
Common Stock      
Liabilities:      
Milestone payment, stock issued as consideration $ 9,300    
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc      
Liabilities:      
Contingent consideration payable   $ 21,766  
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Minimum | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.75  
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Maximum | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.78  
Commercial paper      
Assets:      
Fair value of assets   $ 114,808 115,141
Asset-backed securities      
Assets:      
Fair value of assets   75,255 68,135
Corporate debt securities      
Assets:      
Fair value of assets   139,745 240,726
U.S. government agency bonds      
Assets:      
Fair value of assets   17,666  
Money market funds      
Assets:      
Fair value of assets   4,328 3,082
Level 2      
Assets:      
Fair value of assets   351,802 427,084
Liabilities:      
Contingent consideration payable   0 0
Deferred compensation plan liability   4,003 2,732
Fair value of liabilities   4,003 2,732
Fair value of the Convertible Notes   4,200  
Level 2 | Commercial paper      
Assets:      
Fair value of assets   114,808 115,141
Level 2 | Asset-backed securities      
Assets:      
Fair value of assets   75,255 68,135
Level 2 | Corporate debt securities      
Assets:      
Fair value of assets   139,745 240,726
Level 2 | U.S. government agency bonds      
Assets:      
Fair value of assets   17,666  
Level 2 | Money market funds      
Assets:      
Fair value of assets   4,328 3,082
Level 3      
Liabilities:      
Contingent consideration payable   22,036 19,700
Deferred compensation plan liability   0 0
Fair value of liabilities   $ 22,036 $ 19,700
Level 3 | ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.098